This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/ontology/domain/vavai/cep/zivotniCyklusProjektu/
n16http://linked.opendata.cz/ontology/domain/vavai/cep/typPojektu/
n5http://linked.opendata.cz/ontology/domain/vavai/cep/druhSouteze/
dctermshttp://purl.org/dc/terms/
n2http://linked.opendata.cz/resource/domain/vavai/projekt/
n19http://linked.opendata.cz/resource/domain/vavai/subjekt/
n9http://linked.opendata.cz/resource/domain/vavai/cep/prideleniPodpory/
n15http://linked.opendata.cz/ontology/domain/vavai/
n4http://linked.opendata.cz/ontology/domain/vavai/cep/kategorie/
n12http://linked.opendata.cz/ontology/domain/vavai/cep/duvernostUdaju/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n18http://linked.opendata.cz/ontology/domain/vavai/cep/fazeProjektu/
n6http://linked.opendata.cz/ontology/domain/vavai/cep/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/cep/statusZobrazovaneFaze/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/domain/vavai/projekt/7E11043/
xsdhhttp://www.w3.org/2001/XMLSchema#
n3http://linked.opendata.cz/ontology/domain/vavai/cep/
n8http://linked.opendata.cz/resource/domain/vavai/cep/vyzva/
n20http://linked.opendata.cz/resource/domain/vavai/aktivita/
n17http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:7E11043
rdf:type
n15:Projekt
rdfs:seeAlso
http://www.isvav.cz/projectDetail.do?rowId=7E11043
dcterms:description
Optimise will focus on two goals: optimising current treatments of Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, will explore the development of novel treatments and will identify potential mechanisms for new drug development. To achieve these goals we have assembled a European team of experts that is second to none in the world. Together we will pursue the following objectives: -To use MRI to optimise treatment outcome and to facilitate prediction of response to treatment; - To provide a rational basis for antipsychotic choices in the treatment of first episode schizophrenia or schizophreniform disorder; - To improve functional outcome and reduce drug discontinuation by means of psychosocial interventions. - To explore the potential of cannabidiol CBD, a modulator of endocannabinoid functioning, as an alternative to D2 based antipsychotics - To validate a new approach to improve cognitive performance in patients with cognitive deficits on the basis of their genetic make up; - To use theoretically driven neurochemical imaging (PET and MRS) and empirically driven genetic/genomic markers as predictors of response to treatment. Optimise will focus on two goals: optimising current treatments of Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, will explore the development of novel treatments and will identify potential mechanisms for new drug development. To achieve these goals we have assembled a European team of experts that is second to none in the world. Together we will pursue the following objectives: -To use MRI to optimise treatment outcome and to facilitate prediction of response to treatment; - To provide a rational basis for antipsychotic choices in the treatment of first episode schizophrenia or schizophreniform disorder; - To improve functional outcome and reduce drug discontinuation by means of psychosocial interventions. - To explore the potential of cannabidiol CBD, a modulator of endocannabinoid functioning, as an alternative to D2 based antipsychotics - To validate a new approach to improve cognitive performance in patients with cognitive deficits on the basis of their genetic make up; - To use theoretically driven neurochemical imaging (PET and MRS) and empirically driven genetic/genomic markers as predictors of response to treatment.
dcterms:title
Optimisation of Treatment and Management of Schizophrenia in Europe Optimisation of Treatment and Management of Schizophrenia in Europe
skos:notation
7E11043
n3:aktivita
n20:7E
n3:celkovaStatniPodpora
n14:celkovaStatniPodpora
n3:celkoveNaklady
n14:celkoveNaklady
n3:datumDodatniDoRIV
2015-04-02+02:00
n3:druhSouteze
n5:RP
n3:duvernostUdaju
n12:C
n3:fazeProjektu
n18:101088664
n3:hlavniObor
n6:FL
n3:kategorie
n4:ZV
n3:klicovaSlova
Schizophrenia treatment, MRI, Psycho-educational intervention, cannabidiol, neurochemical predictors, genomics, metabolomics, proteomics
n3:partnetrHlavni
n19:orjk%3A11150
n3:pocetKoordinujicichPrijemcu
0
n3:pocetPrijemcu
1
n3:pocetSpoluPrijemcu
0
n3:pocetVysledkuRIV
0
n3:pocetZverejnenychVysledkuVRIV
0
n3:posledniUvolneniVMinulemRoce
2014-03-20+01:00
n3:prideleniPodpory
n9:13595%2F2011
n3:sberDatUcastniciPoslednihoRoku
n17:2015
n3:sberDatUdajeProjZameru
n17:2015
n3:statusZobrazovaneFaze
n11:DRRVK
n3:typPojektu
n16:P
n3:ukonceniReseni
2015-12-31+01:00
n3:zahajeniReseni
2011-01-01+01:00
n3:zivotniCyklusProjektu
n13:ZBBBK
n3:vyzva
n8:FP7-Health-2009-two-stage
n3:klicoveSlovo
metabolomics neurochemical predictors genomics Schizophrenia treatment Psycho-educational intervention cannabidiol MRI